
In chronic hepatitis B patients treated with nucleos(t)ides, pegIFN-α add-on improves T cell responses and HBsAg decline, particularly in those with lower baseline HBcrAg levels. HBcrAg may help identify patients likely to benefit from pegIFN-α therapy.
Like
Save
Share